Related Experiment Video

Updated: Aug 23, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation

Terence K Lee1, Kwan Man, Joanna W Ho

  • 1Centre for the Study of Liver Disease and Department of Surgery, University of Hong Kong, Pokfulam, Hong Kong, China.

Carcinogenesis
|August 7, 2004
PubMed

Insights

The novel immunomodulator FTY720 effectively induces apoptosis in hepatoma cells, both in vitro and in vivo. This anticancer effect is achieved through phosphoinositide 3-kinase (PI3-K)-mediated Akt dephosphorylation, independent of p53 status.

Area of Science:

  • Hepatocellular Carcinoma Research
  • Cancer Biology
  • Immunomodulation

Background:

  • Hepatocellular carcinoma (HCC) remains a significant global health challenge.
  • Novel therapeutic strategies targeting cancer cell survival and apoptosis are urgently needed.
  • FTY720 (Fingolimod) is an emerging immunomodulator with potential anticancer properties.

Purpose of the Study:

  • To investigate the anticancer effects of FTY720 on hepatoma cell lines in vitro and in a tumor model in vivo.
  • To elucidate the molecular mechanisms underlying FTY720's action, focusing on cell cycle regulation, survival, and apoptosis pathways.

Main Methods:

  • In vitro studies utilized three hepatoma cell lines (HepG2, Huh-7, Hep3B) and one non-tumorigenic liver cell line (MIHA).
  • In vivo efficacy was assessed using a nude mouse tumor model.
  • Analysis included cell cycle distribution, apoptosis markers (caspase-3, caspase-9), and key signaling pathways (PI3-K/Akt, MAPK).

Main Results:

  • FTY720 selectively induced apoptosis in hepatoma cells, evidenced by increased cleaved caspase-3 and caspase-9, without affecting normal liver cells.
  • The drug inhibited the PI3-K/Akt pathway, leading to Akt dephosphorylation at Ser473.
  • This resulted in down-regulation of p42/p44, altered Forkhead transcription factor and GSK-3beta phosphorylation, and subsequent cell cycle changes (up-regulation of p27(Kip1), down-regulation of cyclin D1).
  • In vivo, FTY720 suppressed tumor growth via Akt pathway down-regulation with no significant side effects on normal liver tissue.

Conclusions:

  • FTY720 demonstrates significant anticancer activity against hepatoma cells both in vitro and in vivo.
  • The mechanism involves PI3-K-mediated Akt dephosphorylation, leading to apoptosis and cell cycle arrest.
  • FTY720 represents a promising novel therapeutic agent for hepatocellular carcinoma, acting in a p53-independent manner.

More Related Videos

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death09:18

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death

Published on: December 27, 2016

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...